Findings of one study21 showed that bevacizumab has sustained effects on VEGF inhibition more than 6 weeks after dosing, and findings of several rectal cancer trials in which bevacizumab was used in conjunction with neoadjuvant chemotherapy or chemoradiotherapy showed increased rates of post-operative complications.22, 23, 24, 25 Tumour and blood specimens were collected at baseline in this trial and will be used to investigate whether patients susceptible to long-term effects of bevacizumab such as impaired wound healing can be identified. This evidence concerns the gene VEGFA and neoplasm.